Ignite Creation Date:
2025-12-24 @ 4:47 PM
Ignite Modification Date:
2025-12-31 @ 7:52 AM
Study NCT ID:
NCT06637150
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-10-15
First Post:
2024-09-28
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Dalpicilib-Enhanced Vs. Standard Endocrine Therapy in ER+ HER2- Early Breast Cancer
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D001943', 'term': 'Breast Neoplasms'}], 'ancestors': [{'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D001941', 'term': 'Breast Diseases'}, {'id': 'D012871', 'term': 'Skin Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 1388}}, 'statusModule': {'overallStatus': 'ACTIVE_NOT_RECRUITING', 'startDateStruct': {'date': '2024-09-01', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2024-10', 'completionDateStruct': {'date': '2030-09-30', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2024-10-09', 'studyFirstSubmitDate': '2024-09-28', 'studyFirstSubmitQcDate': '2024-10-09', 'lastUpdatePostDateStruct': {'date': '2024-10-15', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2024-10-15', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2030-09-30', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Invasive Disease Free Survival', 'timeFrame': 'From enrollment to 3 years post-treatment', 'description': 'Invasive Disease Free Survival'}], 'secondaryOutcomes': [{'measure': '3-Year Disease-Free Survival', 'timeFrame': 'From enrollment to 3 years post-treatment'}, {'measure': 'Overall Survival', 'timeFrame': 'From enrollment to 3 years post-treatment', 'description': 'Overall Survival'}, {'measure': 'safety', 'timeFrame': 'From enrollment to 3 years post-treatment', 'description': 'Number of participants with treatment-related adverse events as assessed by CTCAE v4.0'}, {'measure': 'Patient reported outcomes', 'timeFrame': 'From enrollment to 3 years post-treatment', 'description': "Patient-Reported Outcomes (PROs) Assessed by the EORTC QLQ-C30 Questionnaire. Provide a brief description of what aspects of the patient's health or experience the tool will measure (e.g., quality of life, symptom burden, treatment side effects)."}]}, 'oversightModule': {'isUsExport': False, 'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Breast Cancer']}, 'descriptionModule': {'briefSummary': 'This study aims to conduct a randomized controlled clinical trial to compare the efficacy and safety of dalpicilib combined with endocrine therapy versus standard endocrine therapy in ER-positive, HER2-negative, lymph node-negative patients with risk factors, in order to further optimize the regimen for adjuvant endocrine therapy in breast cancer.'}, 'eligibilityModule': {'sex': 'FEMALE', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '70 Years', 'minimumAge': '18 Years', 'genderBased': True, 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n1. Women aged 18-70 years\n2. ECOG score of 0-1\n3. Histologically confirmed unilateral invasive cancer (regardless of pathology type)\n4. No macroscopic or microscopic tumor residue after surgical resection\n5. Early-stage breast cancer, pathologically confirmed as ER-positive and HER2-negative (ER-positive defined as immunohistochemical detection of ER \\>10% of tumor cells positive; HER2 0-1+ or HER2 2+ but FISH negative, with no amplification, defined as HER2-negative)\n6. Postoperative pathological staging of pT1c or above, N0M0, and meeting one of the following criteria: (1) G3; (2) G2 and meeting one of the following: i. Ki-67 ≥20%; ii. 21-gene recurrence score ≥26 or high genomic risk profile; iii. Age ≤40 years and vascular invasion positive\n7. No prior neoadjuvant treatment\n8. Time from surgery or completion of chemotherapy or radiotherapy (whichever occurs later) to randomization does not exceed 8 weeks\n9. Good postoperative recovery, at least 1 week after surgery\n10. Normal function of major organs, meeting the following criteria: (1) Hematological criteria: HB ≥90 g/L (no blood transfusion in the last 14 days); ANC ≥1.5 × 10\\^9 /L; PLT ≥100 × 10\\^9 /L; (2) Biochemical criteria: TBIL ≤1.5 × ULN (upper limit of normal); ALT and AST ≤3 × ULN; serum Cr ≤1.5 × ULN\n11. Women of childbearing age must use contraception during treatment\n12. Subjects voluntarily join this study, sign informed consent, demonstrate good compliance, and cooperate with follow-up\n\nExclusion Criteria:\n\n1. Bilateral breast cancer or ductal/lobular carcinoma in situ (DCIS/LCIS)\n2. Received treatment for advanced disease\n3. Metastasis at any site\n4. Any tumor \\> T4a (with skin involvement, fixation, inflammatory breast cancer)\n5. Clinically or radiologically suspected malignancy in the contralateral breast not confirmed and requiring biopsy\n6. Received neoadjuvant therapy, including chemotherapy, radiotherapy, and endocrine therapy\n7. History of malignant tumors within the past 5 years (excluding basal cell carcinoma of the skin and cervical carcinoma in situ), including contralateral breast cancer\n8. Patient has been enrolled in other clinical trials\n9. Patient has severe systemic diseases and/or uncontrolled infections that prevent participation in the study\n10. Severe cardiovascular or cerebrovascular diseases within 6 months prior to randomization (e.g., unstable angina, chronic heart failure, uncontrolled hypertension \\>150/90 mmHg, myocardial infarction, or stroke)\n11. Known allergy to relevant medications\n12. Women of childbearing age who refuse contraception during treatment and for 8 weeks after treatment completion\n13. Pregnant or breastfeeding women\n14. Positive pregnancy test before drug administration after joining the trial\n15. Individuals with mental illness or cognitive impairment who cannot understand the trial protocol and its side effects, unable to comply with the protocol and follow-up (systematic assessment required prior to enrollment)\n16. Individuals without personal freedom and independent civil capacity'}, 'identificationModule': {'nctId': 'NCT06637150', 'briefTitle': 'Dalpicilib-Enhanced Vs. Standard Endocrine Therapy in ER+ HER2- Early Breast Cancer', 'organization': {'class': 'OTHER', 'fullName': 'Fudan University'}, 'officialTitle': 'A Phase III Randomized Controlled Trial Comparing Dalpicilib-Enhanced Adjuvant Endocrine Therapy with Standard Adjuvant Endocrine Therapy in ER+ HER2- Lymph Node-Negative Early Breast Cancer with Risk Factors', 'orgStudyIdInfo': {'id': 'SCHBCC-N081'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'ACTIVE_COMPARATOR', 'label': 'standard endocrine therapy', 'description': 'standard endocrine therapy', 'interventionNames': ['Drug: endocrine therapy']}, {'type': 'EXPERIMENTAL', 'label': 'standard endocrine therapy plus dalpicilib', 'description': 'standard endocrine therapy plus dalpicilib', 'interventionNames': ['Drug: Dalpicilib', 'Drug: endocrine therapy']}], 'interventions': [{'name': 'Dalpicilib', 'type': 'DRUG', 'description': 'Dalpicilib 100 mg once daily from day 1 to day 21, every 4 weeks, for a total of 3 years, in combination with endocrine therapy for 5 years.', 'armGroupLabels': ['standard endocrine therapy plus dalpicilib']}, {'name': 'endocrine therapy', 'type': 'DRUG', 'description': 'standard endocrine therapy', 'armGroupLabels': ['standard endocrine therapy', 'standard endocrine therapy plus dalpicilib']}]}, 'contactsLocationsModule': {'locations': [{'city': 'Shanghai', 'country': 'China', 'facility': 'breast cancer institute of Fudan University Cancer Hospital, shanghai, shanghai', 'geoPoint': {'lat': 31.22222, 'lon': 121.45806}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Fudan University', 'class': 'OTHER'}, 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'Professor', 'investigatorFullName': 'Zhimin Shao', 'investigatorAffiliation': 'Fudan University'}}}}